Cargando…

High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia

Autologous chimeric antigen receptor-modified (CAR) T cells with specificity for CD19 showed potent antitumor efficacy in clinical trials against relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL). Contrary to T cells, natural killer (NK) cells kill their targets in a non-antigen-sp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Stephan, Bexte, Tobias, Gebel, Veronika, Kalensee, Franziska, Stolzenberg, Eva, Hartmann, Jessica, Koehl, Ulrike, Schambach, Axel, Wels, Winfried S., Modlich, Ute, Ullrich, Evelyn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025537/ https://www.ncbi.nlm.nih.gov/pubmed/32117200 http://dx.doi.org/10.3389/fimmu.2019.03123

Ejemplares similares

Enhancing Lentiviral and Alpharetroviral Transduction of Human Hematopoietic Stem Cells for Clinical Application
por: Schott, Juliane W., et al.
Publicado: (2019)

Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering
por: Oberschmidt, Olaf, et al.
Publicado: (2019)

Genome-Wide Analysis of Alpharetroviral Integration in Human Hematopoietic Stem/Progenitor Cells
por: Moiani, Arianna, et al.
Publicado: (2014)

Alpharetroviral Vectors: From a Cancer-Causing Agent to a Useful Tool for Human Gene Therapy
por: Suerth, Julia D., et al.
Publicado: (2014)

Advantages and applications of CAR-expressing natural killer cells
por: Glienke, Wolfgang, et al.
Publicado: (2015)

Characterization and Manipulation of the Crosstalk Between Dendritic and Natural Killer Cells Within the Tumor Microenvironment
por: Jacobs, Benedikt, et al.
Publicado: (2021)

Generation of an NFκB-Driven Alpharetroviral “All-in-One” Vector Construct as a Potent Tool for CAR NK Cell Therapy
por: Rudek, Loreen Sophie, et al.
Publicado: (2021)

Interplay between the alpharetroviral Gag protein and SR proteins SF2 and SC35 in the nucleus
por: Rice, Breanna L., et al.
Publicado: (2015)

Immunotherapy with NK cells: recent developments in gene modification open up new avenues
por: Reindl, Lisa Marie, et al.
Publicado: (2020)

Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment
por: Oberschmidt, Olaf, et al.
Publicado: (2017)

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma
por: Merker, Michael, et al.
Publicado: (2020)

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome
por: Pfeiffer, Anett, et al.
Publicado: (2018)

A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma
por: Wagner, Juliane, et al.
Publicado: (2017)

Chimerization Enables Gene Synthesis and Lentiviral Delivery of Customizable TALE-Based Effectors
por: Fang, Yongxing, et al.
Publicado: (2020)

Clonal Dominance With Retroviral Vector Insertions Near the ANGPT1 and ANGPT2 Genes in a Human Xenotransplant Mouse Model
por: Haemmerle, Reinhard, et al.
Publicado: (2014)

Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells
por: Pincha, M, et al.
Publicado: (2011)

Lentiviral gene therapy reverts GPIX expression and phenotype in Bernard-Soulier syndrome type C
por: Martinez-Navajas, Gonzalo, et al.
Publicado: (2023)

P12-15. Replication enhancement of an alphaviral-lentiviral replicating chimeric particle (RCP) vaccine
por: Young, K, et al.
Publicado: (2009)

Potent and reversible lentiviral vector restriction in murine induced pluripotent stem cells
por: Geis, Franziska K., et al.
Publicado: (2017)

Correction to: Potent and reversible lentiviral vector restriction in murine induced pluripotent stem cells
por: Geis, Franziska K., et al.
Publicado: (2017)

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
por: Zhang, Congcong, et al.
Publicado: (2017)

Infection Temperature Affects the Phenotype and Function of Chimeric Antigen Receptor T Cells Produced via Lentiviral Technology
por: Jin, Xin, et al.
Publicado: (2021)

Differences in the phenotypes and transcriptomic signatures of chimeric antigen receptor T lymphocytes manufactured via electroporation or lentiviral transfection
por: Niu, Anna, et al.
Publicado: (2023)

Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma
por: Burger, Michael C, et al.
Publicado: (2023)

Microfluidically supported characterization of responses of Rhodococcus erythropolis strains isolated from different soils on Cu-, Ni-, and Co-stress
por: Cao, Jialan, et al.
Publicado: (2021)

Lentiviral Vectors Expressing Chimeric NEDD4 Ubiquitin Ligases: An Innovative Approach for Interfering with Alpha-Synuclein Accumulation
por: Vogiatzis, Stefania, et al.
Publicado: (2021)

Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion
por: Allan, David S.J., et al.
Publicado: (2021)

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
por: Boissel, Laurent, et al.
Publicado: (2013)

Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity
por: Hermanson, David L., et al.
Publicado: (2015)

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
por: Mehta, Rohtesh S., et al.
Publicado: (2018)

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
por: Yilmaz, Ahmet, et al.
Publicado: (2020)

Chimeric antigen receptor engineered natural killer cells for cancer therapy
por: Zhang, Yalan, et al.
Publicado: (2023)

Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children
por: Merker, Michael, et al.
Publicado: (2017)

PB1715: UNLEASHING NATURAL KILLER (NK) CELLS TO PROMOTE ANTI-LEUKEMIC IMMUNITY
por: Tsoukala, Ioanna, et al.
Publicado: (2023)

Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma
por: Dai, Kai, et al.
Publicado: (2021)

Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
por: Wang, Yan, et al.
Publicado: (2023)

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
por: Grada, Zakaria, et al.
Publicado: (2013)

Co-Expression of an IL-15 Superagonist Facilitates Self-Enrichment of GD(2)-Targeted CAR-NK Cells and Mediates Potent Cell Killing in the Absence of IL-2
por: Bodden, Malena, et al.
Publicado: (2023)

Natural Killer Cell-Based Cancer Immunotherapies: From Immune Evasion to Promising Targeted Cellular Therapies
por: Hofer, Erhard, et al.
Publicado: (2017)

Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
por: Tomuleasa, Ciprian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tom29h1tvt5b915a49rvac4hif